[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343717-105":59,"doc-detail-343717-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","identification-of-dlat-as-a-potential-therapeutic-target-via-a-novel-cuproptosis-related-gene-signature-for-the-prediction-of-liver-cancer-prognosis","Identification of DLAT as a potential therapeutic target via a novel cuproptosis-related gene signature for the prediction of liver cancer prognosis","","Liver cancer prognosis remains poor, and cuproptosis—an emerging form of regulated cell death—has unclear roles in liver cancer development and outcome. This study constructs and validates a cuproptosis-related gene signature for prognostic prediction in liver cancer, using RNA and clinical data from 371 patients and survival modeling with Cox regression and LASSO selection. Functional and pathway enrichment, immune microenvironment analysis, and drug prediction are performed alongside experimental validation of DLAT.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/identification-of-dlat-as-a-potential-therapeutic-target-via-a-novel-cuproptosis-related-gene-signature-for-the-prediction-of-liver-cancer-prognosis/343717/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/identification-of-dlat-as-a-potential-therapeutic-target-via-a-novel-cuproptosis-related-gene-signature-for-the-prediction-of-liver-cancer-prognosis/343717.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in liver cancer?","Question",{"text":112,"@type":113},"The study targets the poor prognosis of liver cancer and the unclear relationship between cuproptosis and liver cancer outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is the cuproptosis-related gene signature built and validated?",{"text":117,"@type":113},"The signature is derived from differential gene expression and linked to overall survival using univariate Cox regression and LASSO, then validated across all patients in the dataset.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the study find about DLAT and clinical prognosis?",{"text":121,"@type":113},"DLAT is identified as a potential prognostic and therapeutic target; higher-risk groups show worse survival, and DLAT supports liver cancer cell migration and proliferation while relating to drug resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343717,1790548809,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Identification of DLAT as a potential therapeutic target via a novel cuproptosis-related gene signature for the prediction of liver cancer prognosis  \nCunbing Xia1,2\\#, Yang Chen3\\#, Yongkang Zhu1,2, Dexuan Chen1,2, Haijian Sun1,2, Tong Shen1,2,  \nVishal G. Shelat4, Vasileios K. Mavroeidis5,6, Giovanni Battista Levi Sandri7, Zhan Wang8, Hong Zhu1,2  \n1Department of General Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine/Jiangsu Province Hospital of Chinese Medicine, Nanjing, China; 2National Famous TCM expert ZHU Yongkang’s Inherited Treatment Room, Nanjing, China; 3Department of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China; 4Department of General Surgery, Tan Tock Seng Hospital, Singapore, Singapore; 5Department of HPB Surgery, University Hospitals Bristol & Weston NHS Foundation Trust, Bristol Royal Infirmary, Bristol, UK; 6Department of Transplant Surgery, North Bristol NHS Trust, Southmead Hospital, Bristol, UK; 7Digestive Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 8Department of General Surgery, Zibo Municipal Hospital, Zibo, China  \nContributions: (I) Conception and design: Z Wang, H Zhu, C Xia; (II) Administrative support: Z Wang, H Zhu; (III) Provision of study materials or patients: Y Chen; (IV) Collection and assembly of data: Y Zhu, T Shen; (V) Data analysis and interpretation: D Chen, H Sun; (VI) Manuscript  \nwriting: All authors; (VII) Final approval of manuscript: All authors.  \n\\#These authors contributed equally to this work.  \nCorrespondence to: Zhan Wang, PhD. Department of General Surgery, Zibo Municipal Hospital, No. 137-139, Huan Highway, Linzi District, Zibo 255400, [China. Email: 510436341@qq.com](China. Email: 510436341@qq.com); Hong Zhu, MD. Department of General Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine/Jiangsu Province Hospital of Chinese Medicine, Nanjing, China; National Famous TCM expert ZHU Yongkang’s Inherited Treatment Room, No. 155 Hanzhong Road, Qinhuai District, Nanjing 210029, [China. Email: njtcm1998@163.com](China. Email: njtcm1998@163.com).  \nBackground: The prognosis for liver cancer (LC) is dismal. Researchers recently discovered cuproptosis, a novel form of controlled cell death whose expression in LC and prognosis are unclear. This study reveals a  \ngene signature to predict LC prognosis.  \nMethods: RNA and clinical data for 371 LC patients were obtained from The Cancer Genome Atlas (TCGA) . Differentially expressed genes (DEGs) were identified by comparing cancerous and normal samples. Genes linked to overall survival (OS) were found using univariate Cox regression and least absolute shrinkage and selection operator (LASSO) . The gene signature was validated across all patients. Gene expression and clinical traits were analyzed, and Kaplan-Meier (KM) curves were generated for high-and low-risk groups. DEGs were used for Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), immune infiltration, and drug prediction analyses. DLAT’s functions were assessed using real-time polymerase chain reaction (RT-PCR), transwell invasion, Cell Counting Kit-8 (CCK-8), colony formation,  \nand drug resistance assays.  \nResults: A total of 12 cuproptosis regulators were discovered in LC and normal liver tissues. A 3-gene signature based on LASSO Cox regression was utilized to categorize TCGA LC patients into low-and highrisk categories. Low-risk patients exhibited better survival than high-risk patients (P\u003C0.05) . Tumor grade, stage, and T stage differed between high-and low-risk groups. Long-term prognosis was well predicted by male subgroup survival studies. We predicted LC patient survival using sex, tumor grade, tumor stage, and risk score. Functional enrichment showed that extracellular matrix (ECM) architecture, channel function, and tumor-associated pathways were enriched in LC, suggesting that cancer related functions were collected.  \nImmune microenvironment inhib","cbCaiatuXyYr9Hbe","https://ap.wps.com/l/cbCaiatuXyYr9Hbe","pdf",3599111,22,"English","# Introduction\n# Methods\n## Patient data and analysis\n## Experimental validation\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"What problem does the study address in liver cancer?\",\"answer\":\"The study targets the poor prognosis of liver cancer and the unclear relationship between cuproptosis and liver cancer outcomes.\"},{\"question\":\"How is the cuproptosis-related gene signature built and validated?\",\"answer\":\"The signature is derived from differential gene expression and linked to overall survival using univariate Cox regression and LASSO, then validated across all patients in the dataset.\"},{\"question\":\"What does the study find about DLAT and clinical prognosis?\",\"answer\":\"DLAT is identified as a potential prognostic and therapeutic target; higher-risk groups show worse survival, and DLAT supports liver cancer cell migration and proliferation while relating to drug resistance.\"}]","Identification of DLAT as a potential therapeutic target via a novel cuproptosis-related gene signature for the prediction of liver cancer prognosis | PDF",1790051911,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf872b933f965ac00838880dee2c8498.webp",983,1287,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4289636db6b5125679e81c4333c7ec03.webp",982,1286,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30eb670cdbb8bf1f96171e04d9739ce6.webp",981,1284,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ae74e46d5aad9bc0d1a4462e165366fc.webp",980,1283]